Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH001 in Bipolar II Disorder with Current Major Depressive Episode
NCT05839509Phase 2Terminated
- Sponsor
- GH Research PLC
- Start
- Apr 2023
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of mebufotenin in Bipolar II disorder (BP-II), sponsored by GH Research PLC. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at Day 7. Started Apr 2023; status: terminated.
02
Drugs
mebufotenin
03
Conditions
Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on NCT05839509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839509.